论文部分内容阅读
目的:探讨前列腺癌患者血清IGF-Ⅰ、PRL及SE-cad水平的变化及临床意义。方法:血清IGF-Ⅰ采用放射免疫分析;fPSA及PRL采用化学发光法;血清SE-cad采用酶联免疫分析法。结果:前列腺增生组患者血清IGF-Ⅰ水平较对照组升高显著(P<0.05);血清PRL含量也较对照组显著升高(P<0.05);SE-cad浓度其测定数值也存在显著性差异(P<0.05)。而前列腺癌患者组血清IGF-Ⅰ水平较对照组升高更为显著(P<0.01);血清PRL含量也较对照组升高极其显著(P<0.01);SE-cad浓度其测定数值升高同样非常显著(P<0.01)。灵敏度分析表明,fPSA+IGF-Ⅰ和fPSA+SE-cad两组灵敏度显著高于fPSA单项测定组;fPSA+PRL组灵敏度略低,但P>0.05。特异性分析则fPSA+SE-cad组fPSA单项测定组显著增高(P<0.05),fP-SA+PRL降低明显,fPSA+IGF-Ⅰ组与单项组差异并不显著(P>0.05)。结论:血清IGF-Ⅰ、PRL及SE-cad水平的变化与前列腺癌的发生关系密切,与fPSA的联合测定可提高诊断的灵敏度及特异性,有助于前列腺癌的辅助诊断。
Objective: To investigate the changes and clinical significance of serum IGF-Ⅰ, PRL and SE-cad in patients with prostate cancer. Methods: Serum IGF-Ⅰin radioimmunoassay; fPSA and PRL using chemiluminescence; serum SE-cad using enzyme-linked immunosorbent assay. Results: The level of serum IGF-Ⅰ in benign prostatic hyperplasia group was significantly higher than that in control group (P <0.05), and the level of PRL in serum was significantly higher than that in control group (P <0.05). The concentration of SE-cad also had significant difference Difference (P <0.05). The level of serum IGF-Ⅰ in patients with prostate cancer was significantly higher than that in control group (P <0.01). The level of serum PRL was also significantly higher than that in control group (P <0.01) Also significant (P <0.01). Sensitivity analysis showed that the sensitivity of fPSA + IGF-I and fPSA + SE-cad two groups was significantly higher than the fPSA single measurement group; fPSA + PRL group slightly lower sensitivity, but P> 0.05. Specificity analysis showed that fPSA + SE-cad group was significantly increased (P <0.05), fP-SA + PRL decreased significantly, fPSA + IGF-Ⅰ group and single group difference was not significant (P> 0.05). Conclusion: The changes of serum IGF-Ⅰ, PRL and SE-cad levels are closely related with the occurrence of prostate cancer. Combined with fPSA can increase the sensitivity and specificity of the diagnosis and contribute to the diagnosis of prostate cancer.